Kornimate/medical-research-clean huggingface dataset:
postoperative hyponatremia - are there gender differences?

Conditions: Hyponatremia

Summary: the proposed study will focus on anesthesia and anesthesia-induced hypotension as a possible cause for postoperative fluid retention and hyponatremia, and investigate gender differences in this response.

30 healthy women and 30 healthy men, who are scheduled for surgery of the middle ear or parotic gland are included in the study. within each gender group, the subjects are randomized to receive perioperative intravenous fluid regimes either based on body weight or lean body mass (lbm). the surgery lasts for at least 3 hours, the intervention period (fluid administration according to protocol) will last 10-12 hours, the study period will be 20-24 hours. blood samples for analysis of plasma sodium, potassium, glucose and osmolality are collected preoperatively and the following morning together with analysis of urine produced during the study period.

Eligibility criteria:
inclusion criteria: * asa physical status i-ii * subjects scheduled for otorinolaryngoiatric surgery in general anesthesia of at least 3 hours duration exclusion criteria: * bmi less than 18 * bmi greater than 33 * diabetes mellitus requiring medication * treatment with diuretics * ace-inhibitors * angiotensin ii antagonists * cortisone * lithium * diseases of the kidney * females: * pregnancy * menopause * endocrine dysfunction influencing menstruation

Keywords: water-electrolyte imbalance
pain education added to conventional physiotherapy program for patients with neck pain

Conditions: Neck Pain; Pain

Summary: purpose: the aim of this study is to examine the effects of pain training applied with conventional physiotherapy on pain, range of motion, disability, kinesiophobia and quality of life in patients with neck pain. methods: the research is planned to be completed within 18 months at istanbul hospital. it is planned to include 40 individualsbetween the ages of 18-65 with neck pain persisting for 3 months or more.individuals will be randomly divided into 2 groups. conventional physiotherapy program will be applied to the first group. conventional physiotherapy will be applied to the second group and neuroscience education will be given.pain intensity will evaluate before and after exercise with 'visual analog scale' (vas), and algometer,range of motion will evaluate with c-rom, kinesiofobia will questioned with tampa kinesiofobia score, quality of life will evaluate with nottingham health profile, whereas the level of neck disability will evaluate before and after exercise with 'neck pain and disability score' (npds). the obtained results will analyze using appropriate statistical methods.

the treatment program will be applied 3 days a week for 8 weeks.each 2 groups; will be evaluated twice, at the beginning of the treatment and at the end of the 8th week. conventional physiotherapy program consists of neck isometric exercises, neck isotonic exercises, stabilization exercises, stretching exercises and posture exercises and physiotherapy agents. neuroscience education; the trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions. posters, pictures, graphics and stories, as well as booklets and videos from explain pain, pain in motion and retrainpain websites will be used in appropriate sessions.

Eligibility criteria:
inclusion criteria: * between the ages of 18-65 * neck pain that persists for 3 months or more exclusion criteria: * patients undergoing cervical surgery * patients with neck pain secondary to neurological or vascular disease or neoplasia * patients with radiculopathy with neurological deficits * patients with a history of inflammatory or infective arthritis of the cervical spine * patients who received a physical therapy program in the last 6 months * patients with pain in the scapula, shoulder, upper extremity or lumbar region that may interfere with neck stabilization exercises
identification of phenotypic factors that predict success for weight loss and long-term weight maintenance

Conditions: Obesity

Summary: the investigational weight management clinic now entitled the weight management program at the university of michigan was created to identify strategies that will result in cost-effective, long term weight management for overweight and obese individuals. the driving hypothesis of the clinic is that the 'one size fits all' philosophy is untenable with a complex disease such as obesity. the clinic will serve as a portal for patients to choose standard clinical care or to explore alternatives from a variety of clinical studies offered through the clinic. these studies will include further investigations into nutrition, the biological basis of weight and weight management and protocols using approved and experimental pharmaceuticals as well as technologies that aid in self-management of weight.


Eligibility criteria:
inclusion criteria: * obese males and females: age \>20 years; obese population defined as bmi \> or = 27 kg/m2 * lean population bmi \ 17 kg/m2 * able and willing to provide written informed consent for the trial exclusion criteria: * evidence of inherited disorders of lipid metabolism. * history of cancer within the last 5 years * human immunodeficiency virus (hiv) antibody positive. * patients with solid organ transplants. * participation in any other clinical trial within 90 days of entry into this trial. * pregnant or lactating females. * uncontrolled thyroid disease * unstable angina or ny heart association class ii failure or above * gastrointestinal disease specifically gi motility disorders * unstable neuropsychiatric disease including major depression/anxiety, eating disorder such as binge eating, bulimia or anorexia * end stage renal or hepatic disease * autoimmune disorders (e.g. sle) * body weight fluctuation of more than 5 kg in the previous 3 months * prior bariatric surgery * a history or current alcohol/substance abuse and change in smoking habits or cessation in the past 6 months. * women of childbearing age must use a reliable form of contraception. * any medical condition, which in the opinion of the investigator would make the patient unsuitable for recruitment, or could interfere with the patient participating in or completing the protocol. * unwilling or unable to consent for the study.
neuronal ceroid lipofuscinosis and associated sleep abnormalities

Conditions: Neuronal Ceroid Lipofuscinosis; Batten's Disease

Summary: neuronal ceroid lipofuscinosis (ncl) also known at batten's disease is the most common neurodegenerative disorder in children. families often report the patient has a sleep disturbance. this is a questionnaire to be completed by the family to better understand the sleep pattern and sleep difficulties experienced by individuals who have been diagnosed with ncl.

neuronal ceroid lipofuscinosis (ncl) is the most common neurodegenerative disorder in children characterized by seizures, blindness, ataxia, myoclonia and loss of cognition. there are 12 clinical types identified with a concurrent genetic abnormality. the diagnosis is determined by gene testing and skin biopsy findings although genetic testing has supplanted skin biopsy in most cases. numberous studies have confirmed the presence of sleep disorder in patients with ncl but these cases were documented over a decade ago. the investigators would like to study the prevalence of sleep disorders in this group of patients. the investigators will distribute a children's sleep habits questionnaire (cshq) to the family of the patient to complete and provide a information regarding the patient's sleep. in addition to the validated sleep questionnaire a separate demographic questionnaire will be given to the family to identify the type of ncl, presence or absence of blindness, presence or absence of seizures, interventions tried to treat sleep disturbance. the last questions of the study are asking for the presence or absence of restless leg syndrome symptoms.

Eligibility criteria:
inclusion criteria: * patient with a known diagnosis of neuronal ceroid lipofuscinosis (ncl) by dna or electron microscopy studies family member completing study must be able to read and understand the children's sleep habits questionnaire (cshq) and demographic questions exclusion criteria: * patient without a confirmed diagnosis of ncl family member completing the study is unable to read and understand the questionnaires

Keywords: neuronal ceroid lipofuscinosis ncl batten's disease children's sleep habits questionnaire restless leg syndrome
effect of extracorporeal shock wave therapy of gastrosoleus trigger points in patients with plantar fasciitis

Conditions: Plantar Fasciitis

Summary: plantar fasciitis is one of the most common causes of heel pain. this study will be performed in the purpose of determination the effects of extracorporeal shock wave therapy of gastrosoleus trigger points in patients with plantar fasciitis

plantar fasciitis is the most common cause of inferior heel pain, a great variety of therapies have been reported for the treatment of plantar fasciitis including extracorporeal shock wave therapy. gastrosoleus muscle dysfunction is one of the most common contributing factors to this disease .despite the long history and the fact that this is a common diagnosis made in clinical practice, the exact cause and best treatment for this condition still are being explored. although there is lack of high-quality studies demonstrating the efficacy of extracorporeal shock wave therapy of gastrosoleus trigger points in patients with plantar fasciitis , this study will be performed to examine the effect of extracorporeal shock wave therapy of gastrosoleus trigger points in patients with plantar fasciitis

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of plantar fasciitis 2. having at least one gastrosoleus trigger point concomitantly. 3. having no response to conservative treatments for at least 3 months 4. willingness to participate exclusion criteria: 1. dysfunction of the knee or ankle 2. neurologic abnormalities 3. bleeding tendency (hereditary or acquired) 4. nerve entrapment syndrome 5. a previous operation on the heel 6. pregnancy 7. evidences of infection in lower limbs 8. a medical history of tumor 9. previous local corticosteroid injection within 12 weeks
evaluation of pigmented skin lesions with melafind(r) system

Conditions: Melanoma

Summary: the purpose of this clinical trial is to demonstrate that melafind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective. melafind® acquires digital images of the lesion with illumination in different spectral bands, from visible to near infrared, and automatically analyzes these images. diagnostic accuracy of melafind® and that of study dermatologists will be evaluated. the reference standard will be final interpretation of lesions by central dermatohistopathology.


Eligibility criteria:
inclusion criteria: * the lesion is pigmented (i.e., melanin, keratin, blood) * clinical management of the lesion by the examining dermatologist is either biopsy of the lesion in toto, or 3-month follow-up of the lesion * the diameter of the pigmented area is between 2 and 22 millimeters * the lesion is accessible to the melafind hand-held imaging device * the patient, or a legally authorized representative, has consented to participate in the study and has signed the informed consent form exclusion criteria: * the patient has a known allergy to isopropyl alcohol * the lesion has been previously biopsied, excised, or traumatized * the skin is not intact (e.g., open sores, ulcers, bleeding) * the lesion is within 1 cm of the eye * the lesion is on mucosal surfaces (e.g., lips, genitals) * the lesion is on palmar hands * the lesion is on plantar feet * the lesion is on or under nails * the lesion is located on or in an area of visible scarring * the lesion contains foreign matter (e.g., tattoo, splinter, marker)

Keywords: pigmented skin lesions dermatology skin cancer melanoma melafind
effect of drast on treatment for bacteremia in patients with hematologic diseases

Conditions: Hematologic Diseases; Bacteremia Sepsis

Summary: the purpose of this study is to evaluate whether the use of direct rapid antibiotic susceptibility test (drast), in addition to the current standard antibiotic susceptibility test, can increase the proportion of patients with hematologic disease who received appropriate antibiotics in early period of bacteremia.

* patients with hematologic diseases who have high risk of bacteremia, because of immune suppression treatment or intensive chemotherapy or bone marrow transplantation which these patients had received, will be recruited in tertiary referral medical centers. * all the participants will be randomly assigned into either drast group or current standard antibiotic susceptibility test group. * all the participants in the both arms will receive antimicrobial stewardship by infectious disease specialists. antimicrobial stewardship will be performed at each timepoint of gram stain results reporting, drast results reporting, and current method reporting. * target numbers are 58 and 58, respectively. * all the participants will be monitored for general medical conditions such as vital sign and response to antibiotic treatment by infectious disease specialists for 1 week. * the percentage of patients who received optimal targeted antibiotics 72 hours after blood collection for blood culture will be evaluated.

Eligibility criteria:
inclusion criteria: * patients who are expected to be admitted for more than 2 days due to treatment or complications of hematologic diseases (acute leukemia, chronic leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, aplastic anemia, etc.) in seoul national university hospital. * patients with confirmed bacteremia * patients who can understand the details of the clinical trial's explanation and provide the written consent exclusion criteria: * patients who are expected to stay in the hospital within 2 days * patients without bacteremia during hospitalization * patients who show fungemia without evidence of bacteremia

Keywords: bacteremia optimal targeted antibiotics antibiotic susceptibility test antimicrobial stewardship
use of lipogems for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: lipogems system consist in the use of a monouse kit for liposuction, processing and administration of adipose tissue. the use of the final product (microfragmented adipose tissue,not expanded) shoud promote the natural joint homeostasis, associated with a clinical improvement

the objectiveof the study is to analyse the therapeutic role of microfragmented autologous tissue for the treatment of the knee osteoarthritis (oa). main purpose: symptomatic and functional evaluation at 6 months by comparison of the knee injury and osteoarthritis outcome score(koos) recorded between two groups (6±1 months) undergoing arthroscopic debridement ± injection of autologous microfragmented lipoaspirate tissue (lipogems®). secondary purposes: evaluation of possible radiological changes pre-operative and after 6±1 months by means of magneticresonanceimage analysis. symptomatic and functional evaluation at 6±1 months by means of visualanaloguescale, kneesocietyscore, western ontario and mcmaster universities osteoarthritis index(womac). reduction of anti-inflammatory drugs (pre-intervention versus 6±1 months). evaluation "quality-adjusted life years" (qualy) in relation to the questionnaire satisfactioform-12 (pre-intervention vs 6±1 months). check for any adverse effects directly related to the use of micro-fragmented adipose tissue. changes in serum levels of biomarkers related to oa (collagentype ii c-telopeptide (ctx-ii), collagen type iii n-propeptide (piiinp)) will be evaluated (pre-intervention vs 6±1 months). the study is an interventional, prospective, randomized, controlled trial. controls: n = 39 patients with knee osteoarthritis undergoing arthroscopic debridement. cases: n = 39 patients with knee osteoarthritis undergoing arthroscopic debridement surgery + intrarticular injection of autologous microfragmented lipoaspirate tissue (lipogems®). surgical technique: patient in supine position. a double contemporary operating fields is made under sedation. during arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of klein solution. the plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. then lipoaspirate was processed with lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. a volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.

Eligibility criteria:
inclusion criteria: * patients with knee osteoarthritis grade iii e iv kellgren-lawrence, * age between 45 and 75, * pain ≥ 6 vas scale, * no ligamentous instability,axial deviation less than 10° * bmi between 18 and 30, * international normalized ratio (inr) \< 1.5 exclusion criteria: * previous traumatic lesion (tibial fracture, osteothomy) of the knee * osteonecrosis * meniscal surgery in the previous 6 weeks * chemiotherapy, radioteherapy * diabetes * alchoolism, psichiatric disease,drug addiction * coagulation disorders * pregnancy
umbilical cord blood transfusion in consolidation therapy of elderly patients with acute myeloid leukemia

Conditions: Leukemia, Myelomonocytic, Acute

Summary: after complete remission, elderly aml patients cannot tolerate hematopoietic stem cell transplantation and standard-dose consolidation chemotherapy, and the 5-year survival rate is around 10%. therefore, it is necessary to explore treatment strategy that can support chemotherapy or improve immunity. umbilical cord blood is rich in hematopoietic stem cells and immune cells. however,cord blood transplantation for adults is still being explored. the application of cord blood in supportive treatment can be actively explored. cord blood has low immunogenicity and is unlikely to cause graft versus host disease (gvhd), and the infusion is relatively safe. the department of hematology of shanghai ruijin hospital has conducted a related phase ii clinical study, and found that cord blood transfusion reduced the chance of infection and increased the 2-year survival. our subject is a prospective single-arm clinical study. it is planned to recruit 20 elderly aml patients to explore whether the application of cord blood infusion can further improve the prognosis of patients during their consolidation chemotherapy.

20 elderly aml patients who achieved complete remission (cr) after induction chemotherapy will be enrolled in this study. baseline data are collected and informed consents are signed before consolidation chemotherapy. at the same time, hla typing test is carried out, and the corresponding cord blood is matched from the cord blood bank. during the consolidation chemotherapy stage, the cord blood transfusion is given twice (interval of 1 month) to support treatment. on the first day after umbilical cord blood transfusion, the proportion of nk cells in peripheral blood are detected. if it is less than 20%, the nk cells are activated by subcutaneous injection of recombinant human interleukin-2 (rhil-2) on the second day after infusion. the treatment effects are continuously monitored and followed up regularly after treatment.the intend of this trial is to explore whether cord blood transfusion in the consolidation phase can further reduce the recurrence rate of aml and improve prognosis.

Eligibility criteria:
inclusion criteria: * age ≥60 years * patients with primary aml diagnosed in accordance with the "adult acute myeloid leukemia (non-acute promyelocytic leukemia) chinese diagnosis and treatment guidelines (2017 edition)", who achieved cr after induction chemotherapy * normal heart function , ejection fraction ≥ 50% * normal liver function with alt and ast ≤ 2.5 times the upper limit of normal value, bilirubin ≤ 2 times the upper limit of normal value * normal kidney function with blood creatinine ≤ 3.0 mg/dl (≤ 260 µmol/l) * voluntarily signed an informed consent. exclusion criteria: * combined with severe infection * combined with other malignant tumors * other patients deemed unsuitable to be tested by the investigator

Keywords: leukemia, myelomonocytic, acute umbilical cord blood transfusion treatment effect
therapeutic drug monitoring in patients with difficult-to-treat gram-negative bacterial infections

Conditions: Sepsis; Hemodynamic Instability; Bacterial Infections; Therapeutic Drug Monitoring; Antimicrobial Resistance

Summary: a prospective, open-label, randomized controlled trial will be conducted to evaluate a novel tdm-guided therapy in management of dt-gnb infections. we hypothesize that tdm-guided antibiotic therapy will reduce 14-day all-cause mortality by 6% (absolute risk reduction) in septic patients with dt-gnb infections, when compared to standard therapy. tdm for 11 antibiotics will be performed for all trial patients although test information will be withheld for the standard therapy arm. the primary aim is to compare the 14-day all-cause mortality rates of novel tdm-guided antibiotic dosing versus standard therapy.

sepsis remains a major cause of morbidity and mortality worldwide in the face of antimicrobial resistance especially in patients with gram-negative bacteria (gnb) infections. limited new antibiotics for gnb infections pose a severe threat to clinical management of these patients and thus call for old antibiotics to be repurposed. dosing regimens of old antibiotics often fail to achieve therapeutic drug concentrations in some septic patients. septic patients commonly have significant hemodynamic changes and/or undergo extracorporeal interventions that may increase patients' susceptibility to treatment failure and increase the chance of more resistant bacteria emergence, or toxicity from the antibiotic. hence, the "one size fits all" dosing principle for antimicrobial treatments of suspect sepsis due to infection by antibiotic-resistant- or less susceptible-gnb \[collectively known as "difficult-to-treat" (dt)-gnb infections\] is no longer viable. this will require therapeutic drug monitoring (tdm) to inform if the dosing is adequate to treat such infections. this study seeks to provide evidence supporting the application of tdm-guided antibiotic therapy on reducing mortality and morbidity among septic patients with dt-gnb infections and significant hemodynamic changes, which can potentially shift current practice paradigms.

Eligibility criteria:
inclusion criteria: * 16 years or older * receive intravenous therapy of the study antibiotics * antibiotic treatment should be aimed for at least 3 days at time of inclusion exclusion criteria: * pregnancy * antibiotics cessation before first blood sample collection * receiving antibiotics only as prophylaxis * on palliative care or with less than 48 hours of life expectancy

Keywords: sepsis hemodynamic instability therapeutic drug monitoring gram-negative bacteria beta-lactams fosfomycin fluoroquinolone glycylcycline dialysis